Eli Lilly and Company revenue growth has been varied year-over-year.

What is LLY's revenue growth rate?

Historical revenue data is available for Eli Lilly and Company to analyze growth trends.

How fast is LLY earnings growing?

Earnings growth data is available for Eli Lilly and Company analysis.

What is LLY's profit margin?

Profit margin data is available for Eli Lilly and Company.

LLY Revenue & Earnings Growth Analysis 2026 - Is Eli Lilly and Company Growing?

Growth Summary

Eli Lilly and Company (LLY) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.

Over the past 4 years, Eli Lilly and Company has achieved a revenue compound annual growth rate (CAGR) of 17.6%, while earnings have grown at 40.9% CAGR.

Latest Revenue

$65.18B

Net Income

$20.64B

5-Year Revenue CAGR

17.6%

4 years of data

Net Margin

N/A

Latest period

Revenue Growth Over Time

Historical revenue and profitability trends for Eli Lilly and Company

The chart above illustrates Eli Lilly and Company's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.

Year-over-Year Growth Rates

Annual percentage change in revenue and earnings

Growth rates provide insight into the momentum of Eli Lilly and Company's business.

Profit Margin Trends

How efficiently Eli Lilly and Company converts revenue into profit

Understanding Profit Margins

Profit margins reveal how much of each dollar of revenue Eli Lilly and Company retains at different stages:

Gross Margin (N/A%): What remains after direct production costs
Operating Margin (N/A%): Profit from core operations before interest and taxes
Net Margin (N/A%): Final profit after all expenses

Future Growth Outlook

Analyst estimates and forward-looking indicators

EPS Estimate 2026

$34.46

Current: $23.00

EPS Estimate 2027

$41.88

21.5% expected growth

Price Target

$1214.34

Analyst consensus

What Analysts Are Saying

Wall Street analysts project Eli Lilly and Company to continue growing earnings in the coming year. The consensus analyst rating is 4.2414 based on 29 analysts.

Growth Analysis Conclusion

Based on our comprehensive analysis, Eli Lilly and Company (LLY) demonstrates declining growth characteristics.

Key Takeaways:

Revenue Growth:, 17.6% CAGR over 4 years
Profitability: demonstrates the company is profitable
Efficiency:

Investment Considerations

This growth analysis provides a comprehensive view of Eli Lilly and Company's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.